Viikinkoski, Emma
Jalkanen, Juho
Gunn, Jarmo
Vasankari, Tuija
Lehto, Joonas
Valtonen, Mika
Biancari, Fausto
Jalkanen, Sirpa
Airaksinen, K. E. Juhani
Hollmén, Maija
Kiviniemi, Tuomas O.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Red blood cell transfusion induces abnormal HIF-1α response to cytokine storm after adult cardiac surgery
https://doi.org/10.1038/s41598-021-01695-4
Funding for this research was provided by:
Turun Yliopistollisen Keskussairaalan Koulutus- ja Tutkimussäätiö
Turun Yliopisto
Orionin Tutkimussäätiö
Sydäntutkimussäätiö
Emil Aaltosen Säätiö
Suomen Kulttuurirahasto
Suomen Lääketieteen Säätiö
Suomen Kardiologinen Seura
Maud Kuistilan Muistosäätiö
Article History
Received: 6 May 2021
Accepted: 1 November 2021
First Online: 15 November 2021
Competing interests
: Joonas Lehto received research grants from Orion Research Foundation, the Finnish Foundation for Cardiovascular Research, the Finnish Cultural Foundation, Turku University Foundation, and Emil Aaltonen Foundation. K. E. Juhani Airaksinen received research grants from the Finnish Foundation for Cardiovascular Research, the Clinical Research Fund (VTR) of Turku University Hospital, Turku, Finland and lecture fees from Bayer, and Boehringer Ingelheim. K. E. Juhani Airaksinen is a member in the advisory boards of Bayer, Astra Zeneca, and Bristol-Myers Squibb-Pfizer. Jarmo Gunn received research grants from Turku University Research Foundation, Turku, Finland, the Clinical Research Fund (VTR) of Turku University Hospital, Turku, Finland, and an unrestricted grant from Vifor Pharma. Tuomas O. Kiviniemi received lecture fees from Bayer, Boehringer Ingelheim, MSD, Astra Zeneca, St Jude Medical, and Bristol-Myers-Squibb-Pfizer, and research grants from the Finnish Medical Foundation, the Finnish Foundation for Cardiovascular Research, Clinical Research Fund (EVO) of Turku University Hospital, Turku, Finland, Finnish Cardiac Society, the Emil Aaltonen Foundation, the Maud Kuistila Foundation, and an unrestricted grant from Bristol-Myers Squibb-Pfizer. Tuomas O. Kiviniemi is a member of the advisory board of Boehringer-Ingelheim, and MSD. Juho Jalkanen owns stock and is employed by Faron Pharmaceuticals Ltd. The other authors declare no competing interests.